MSD

News

MSD, Eisai report setback in first-line kidney cancer trial

The LITESPARK-012 trial saw no benefit when Welireg was added to treatment with Keytruda plus Lenvima for renal cell carcinoma.

News

Update: Rumour confirmed as MSD buys Terns for $6.7bn

MSD's glut of pipeline-boosting deals in the build-up to a looming patent cliff has continued with a $6.7bn bid to acquire Terns Pharma.

News

MSD taps Quotient for IBD drug targets in $2.2bn deal

MSD is paying $20m upfront to activate an alliance with Flagship's Quotient Therapeutics to find new targets in inflammatory bowel disease.

News

Keytruda cleared for NHS use in early head and neck cancer

MSD's Keytruda is poised to end a 20-year drought in new advances in NHS treatment for early-stage head and neck cancer.

News

MSD splits pharma business, hiving off oncology

MSD is separating its cancer and non-cancer pharma operations as it prepares for the looming loss of patent protection for $31bn blockbuster Keytruda.

News

MSD and Mayo Clinic team up on AI drug discovery

MSD has signed an industry-first deal with the Mayo Clinic that will allow it to use the health system's genomic and clinical data for drug discovery.

MSD, Eisai report setback in first-line kidney cancer trial

Update: Rumour confirmed as MSD buys Terns for $6.7bn

MSD taps Quotient for IBD drug targets in $2.2bn deal

Keytruda cleared for NHS use in early head and neck cancer

MSD splits pharma business, hiving off oncology

MSD and Mayo Clinic team up on AI drug discovery

Novartis weathers Entresto slump with return to growth

Discover a new era of healthcare panel engagement: Grounded ...

MSD

Editor's Picks